AbbVie Inc. (ABBV - Free Report
) announced the submission of a supplemental New Drug Application (sNDA) for its blood cancer drug Imbruvica (ibrutinib) in the U.S.
AbbVie is looking for a label expansion of Imbruvica to include the treatment of marginal zone lymphoma (MZL). MZL is a slow-growing form of non-Hodgkin's lymphoma.
Imbruvica is currently approved in the U.S. for the treatment of patients with MCL or CLL who have received at least one previous therapy and for CLL patients with deletion 17p. It is also approved for the treatment of Waldenstrom's macroglobulinemia. This is the fifth time that AbbVie has filed an sNDA for Imbruvica.
Pharmacyclics LLC, a subsidiary of AbbVie, markets Imbruvica under a partnership with Johnson & Johnson’s (JNJ - Free Report
) Janssen Biotech, Inc.
The sNDA was based on data from a multi-center, open-label phase II PCYC-1121-CA trial assessing Imbruvica as a single-agent treatment for MZL. The study enrolled 63 previously treated patients with MZL. Patients were received once-daily oral administration of ibrutinib alone. The primary endpoint of the overall response rate as assessed by an Independent Review Committee was met.
We remind investors that in Apr 2013, the FDA had granted Breakthrough Therapy designation to ibrutinib for the treatment of CLL/small lymphocytic lymphoma patients, with a deletion of chromosome 17p. Earlier this year, the regulatory agency granted Breakthrough Therapy designation to ibrutinib for the treatment of mantle cell lymphoma patients as monotherapy. The FDA granted also granted Breakthrough Therapy status to the candidate for the treatment of patients suffering from Waldenström's macroglobulinemia as monotherapy. We expect investor focus to remain on the further development of ibrutinib.
AbbVie expects Imbruvica peak sales of over $7 billion and revenues of about $5 billion in 2020. We believe Imbruvica has multi-billion dollar potential and AbbVie is working on expanding Imbruvica’s label to include solid tumors and autoimmune diseases. The company sees Imbruvica as a “pipeline in a molecule” given that the treatment is presently in several company-sponsored studies. A registrational study for graft-versus-host disease is underway, with data expected later this year or early 2017.
We remind investors that Imbruvica was added to AbbVie’s portfolio following its Pharmacyclics acquisition in May 2015.
AbbVie currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 20.3% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, over the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 48.3% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>